Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite

Drug Metabolism and Disposition

Volumn 24, Issue 12, 1996, Pages 1401-1403

  Bajpai, Manoj ^a,b   Roskos, Lorin K ^a,b   Shen, Danny D ^b   Levy, René H ^a,b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; CYTOCHROME P450; DRUG METABOLITE; PHENYTOIN;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS CONSTANT; PRIORITY JOURNAL; STEREOCHEMISTRY;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PHENYTOIN; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030454133     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. T. R. Browne and B. LeDuc: Phenytoin: chemistry and biotransformation. In "Antiepileptic Drugs" (R. H. Levy, R. H. Mattson, and B. S. Meldrum, eds.), pp. 329-338. Raven Press Ltd., New York, 1995.
2. R. B. Knodell, S. D. Hall, G. R. Wilkinson, and F. P. Guengerich: Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241, 1112-1119 (1987).
3. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37, 1137-1144 (1988).
4. H. S. Purba, D. J. Back, and M. L. E. Orme: Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br. J. Clin. Pharmacol. 24, 230-234 (1987).
5. M. V. Relling, T. Aoyama, F. J. Gonzalez, and U. A. Meyer: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447 (1990).
6. P. K. Srivastava, C. H. Yun, P. H. Beaune, C. Ged, and F. P. Guengerich: Separation of human liver microsomal tolbutamide hydroxylase and (R)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69-79 (1991).
7. S. D. Hall, F. P. Guengerich, R. A. Branch, and G. R. Wilkinson: Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther. 240, 216-222 (1987).
8. T. Shimada, S. K. Misono, and F. P. Guengerich: Human liver microsomal cytochrome P450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 909-921 (1986).
9. M. E. Veronese, P. I. Mackenzie, C. J. Doecke, M. E. McManus, J. O. Miners, and D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
10. C. J. Doecke, M. E. Veronese, S. M. Pond, J. O. Miners, D. J. Birkett, L. N. Sansom, and M. E. McManus: Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31, 124-130 (1990).
11. R. H. Levy and M. Bajpai: Phenytoin: interactions with other drugs: mechanistic aspects. In "Antiepileptic Drugs" (R. H. Levy, R. H. Mattson, and B. S. Meldrum, eds.), pp. 329-338. Raven Press Ltd., New York, 1995.
12. R. H. Levy, F. Bishop, A. J. Streeter, W. F. Trager, K. L. Kunze, K. T. Thummel, and G. G. Mather: Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia 36, 47 (1995).
13. P. Unge, L. E. Svedberg, A. Nordgren, H. Glom, T. Andersson, P. O. Lagerstrom, and J. P. Idstrom: A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34, 509-512 (1992).
14. I. Niopas, S. Toon, and M. Rowland: Further insight into the stereoselective interaction between warfarin and cimetidine in man. Br. J. Clin. Pharmacol. 32, 508-511 (1991).
15. C. Stockley, J. Real, P. Rolan, F. Bochner, and A. Somogyi: Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur. J. Clin. Pharmacol. 31, 235-237 (1986).
16. W. F. Trager, K. L. Kunze, K. Thummel, L. Wienkers, F. Bishop, M. Bajpai, G. G. Mather, and R. H. Levy: Prediction of phenytoin interactions based on cytochrome P450 isoforms. Epilepsia 35, 143 (1994).
17. K. Chiba, K. Kobayashi, K. Manabe, M. Tani, T. Kamataki, and T. Ishizaki: Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266, 52-59 (1993).
18. S. Fritz, W. Linder, I. Roots, B. M. Frey, and A. Kupfer: Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 241, 615-622 (1987).
19. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275, 1951.
20. D. Roy and W. R. Snodgrass: Isocratic separation of phenytoin metabolites by high performance liquid chromatography from human and animal microsomes and urine. Ther. Drug Monit. 11, 57-62 (1989).
21. K. Chiba, K. Kobayashi, K. Manabe, M. Tani, T. Kamataki, and T. Ishizaki: Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur. J. Clin. Pharmacol. 44, 559-562 (1993).
22. L. K. Roskos, F. E. Bishop, W. L. Nelson, and D. D. Shen: Enantioselective and diastereoselective aspects of bufuralol benzylic hydroxylation in human liver microsomes. Pharmaceut. Res. 10, S-3 (1993).
23. W. R. Porter, R. V. Branchflower, and W. F. Trager: A kinetic method for the determination of the multiple forms of microsomal cytochrome P-450. Biochem. Pharmacol. 26, 549-550 (1977).
24. M. E. Veronese, C. J. Doecke, P. I. Mackenzie, M. E. McManus, J. O. Miners, D. L. P. Rees, R. Gasser, U. A. Meyer, and D. J. Birkett: Site directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J. 289, 533-538 (1993).
25. M. E. Krecic, D. R. Shepard, T.-H. Chang, J. Collins, and N. Gerber: Stereoselective metabolism of phenytoin by hepatic microsomes and human CYP2C9 and CYP2C18 expressed in yeast. ISSX Proc. 8, 370 (1995).